D3 Bio (Wuxi) Co., Ltd
6 clinical trials · Sponsor
◉ Watch D3 Bio (Wuxi) Co., Ltd
| Record | Firm | Date |
|---|---|---|
| Study of D3L-002 in Subjects With Advanced Solid Tumors (NCT07667842) | D3 Bio (Wuxi) Co., Ltd | 2026-07-18 |
| A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation. (NCT07456046) | D3 Bio (Wuxi) Co., Ltd | 2026-05-29 |
| A Phase 1 Study to Assess Food Effect on the Pharmacokinetics of D3S-001 in Healthy Adult Participants (NCT07093398) | D3 Bio (Wuxi) Co., Ltd | 2025-07-11 |
| A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors (NCT05957536) | D3 Bio (Wuxi) Co., Ltd | 2023-09-19 |
| A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (NCT05886920) | D3 Bio (Wuxi) Co., Ltd | 2023-07-10 |
| A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation (NCT05410145) | D3 Bio (Wuxi) Co., Ltd | 2022-08-03 |
Track D3 Bio (Wuxi) Co., Ltd automatically
Every clearance here is in the API, with alerts when new ones post.